Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATINUM study of quetiapine SR maintenance monotherapy in generalized anxiety disorder
2005-005055-18Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in generalized anxiety disorder (GAD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Time from randomization to an anxiety event. Started Jan 2006; status: completed.
02
Drugs
quetiapine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2005-005055-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005055-18.